Conquer Cancer Foundation Report issue

Foundation Phase 1 Phase 2

Organization Overview

First Clinical Trial
2015
NCT02457910
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Conquer Cancer Foundation

Active Ingredients

Drugs in Phase 2 Trials (3)

68ga-psma (1 trial)

enzalutamide (xtandi) (1 trial)

taselisib (1 trial)

Drugs in Phase 1 Trials (1)

tremelimumab (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Breast Neoplasms (Phase 2)

Carcinoma (Phase 1)

Carcinoma, Renal Cell (Phase 1)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 6
  • # of Trial APIs: 4